OAM
BMRN icon

Ostrum Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ostrum Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,208
Closed -$1.58M – 577
2025
Q3 		$1.58M Buy
29,208
+8,121
+39% +$464K 0.07% 232
2025
Q2 		$1.16M Sell
21,087
-235
-1% -$13.8K 0.05% 269
2025
Q1 		$1.51M Sell
21,322
-224
-1% -$15.1K 0.08% 228
2024
Q4 		$1.42M Sell
21,546
-12,103
-36% -$811K 0.12% 255
2024
Q3 		$2.37M Buy
33,649
+253
+0.8% +$21.1K 0.2% 187
2024
Q2 		$2.75M Sell
33,396
-1,596
-5% -$133K 0.24% 139
2024
Q1 		$3.06M Hold
34,992
– – 0.24% 125
2023
Q4 		$3.37M Sell
34,992
-6,179
-15% -$547K 0.29% 94
2023
Q3 		$3.64M Sell
41,171
-2,139
-5% -$190K 0.34% 70
2023
Q2 		$3.75M Sell
43,310
-250
-0.6% -$23.5K 0.31% 86
2023
Q1 		$4.24M Buy
+43,560
New +$4.52M 0.37% 68
2020
Q3 		$1.52M Buy
20,000
+8,500
+74% +$860K 0.98% 24
2020
Q2 		$1.42M Buy
+11,500
New +$1.14M 0.84% 29

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ostrum Asset Management's BMRN Position: Q4 2025 in Review

Ostrum Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 29,208 shares — an estimated $1.58M sold.

Ostrum Asset Management first reported a position in BMRN in Q2 2020 and held it in 13 quarters. The position peaked at $4.24M in Q1 2023. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • Ostrum Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Ostrum Asset Management sold 29,208 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $1.58M.
  • Ostrum Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 13 quarters.
  • Ostrum Asset Management's BioMarin Pharmaceuticals position peaked at $4.24M in Q1 2023.
  • 538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Ostrum Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.